Presentation Controversies and Advances 2017 PCSK9 Inhibitors - Are They Worth The Money? Presenter: Michael J. Blaha November 16, 2017 REGISTER for free or LOG IN to view this content Coronary CAD Pharma Presentation Controversies and Advances 2017 Up Next Presentation Controversies and Advances 2017 New Horizons in Cardiogenic Shock Presenter: Timothy D. Henry November 16, 2017 More slides + Presentation Controversies and Advances 2017 Sex Considerations in the FDA Drug Review Pipeline and Drug Trial Snapshots Presenter: Marjorie R. Jenkins November 16, 2017 Presentation Controversies and Advances 2017 Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Presenter: Sanjay Kaul November 16, 2017 We Recommend
Presentation Controversies and Advances 2017 New Horizons in Cardiogenic Shock Presenter: Timothy D. Henry November 16, 2017
Presentation Controversies and Advances 2017 Sex Considerations in the FDA Drug Review Pipeline and Drug Trial Snapshots Presenter: Marjorie R. Jenkins November 16, 2017
Presentation Controversies and Advances 2017 Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Presenter: Sanjay Kaul November 16, 2017